Table 2.
Statistically significant differences in (A) CD25 and (B) CD86 expression between different CLL subgroups with distinct clonotypic BcRs after stimulation of TLRs and NOD2 with their respective ligands.a
| Evaluated TLR | Compared groups | Median values, % | p |
|---|---|---|---|
| A. CD25 | |||
| TLR1/2 | #1 versus #8 | 30.7 versus 82.8 | 0.050 |
| #4 versus non-#4/16 | 57.85 versus 7.9 | 0.007 | |
| UM versus #8 | 52.4 versus 82.8 | 0.050 | |
| TLR2/6 | #4 versus non-#4/16 | 35.05 versus 10.6 | 0.033 |
| #16 versus non-#4/16 | 47 versus 10.6 | 0.004 | |
| M versus #16 | 22.1 versus 47 | 0.021 | |
| TLR7 | M versus UM | 8.4 versus 50.1 | 0.001 |
| #4 versus #1 | 11 versus 46.8 | 0.026 | |
| UM versus #8 | 50.1 versus 75.6 | 0.028 | |
| TLR9 | #4 versus non-#4/16 | 61.9 versus 32.8 | 0.022 |
| NOD2 | #4 versus non-#4/16 | 27.8 versus 14.7 | 0.019 |
| B. CD86 | |||
| TLR1/2 | #4 versus #1 | 51 versus 11 | 0.034 |
| #4 versus non-#4/16 | 51 versus 9.8 | 0.003 | |
| #16 versus non-#4/16 | 55.5 versus 9.8 | 0.038 | |
| TLR2/6 | #4 versus #1 | 41.4 versus 6.3 | 0.049 |
| #4 versus non-#4/16 | 41.4 versus 15.3 | 0.022 | |
| #16 versus non-#4/16 | 41.1 versus 15.3 | 0.002 | |
| M versus #16 | 21.3 versus 41.1 | 0.004 | |
| TLR7 | UM versus #8 | 4.2 versus 18.3 | 0.034 |
| TLR9 | M versus UM | 40.4 versus 8.2 | 0.001 |
| #4 versus #1 | 56.8 versus 4.3 | 0.001 | |
| #4 versus #16 | 56.8 versus 24.9 | 0.031 | |
| #1 versus #8 | 4.3 versus 26.8 | 0.048 | |
| NOD2 | #4 versus #1 | 31.5 versus 2.8 | 0.001 |
| #4 versus non-#4/16 | 31.5 versus 16.2 | 0.019 | |
| M versus #4 | 15.2 versus 31.5 | 0.021 | |
a
Before statistical analysis values were normalized to the unstimulated controls.
M, mutated; UM, unmutated.